Tony Berberabe

Articles

Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis

December 11th 2024

Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.

Anito-Cel Yields 100% Response Rate in R/R Myeloma

September 30th 2024

All patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.

Adjuvant Pembrolizumab Prolongs DFS Regardless of PD-L1 or Nodal Status in High-Risk MIBC

September 25th 2024

Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.

Novel Cell-Free DNA Assays Expand the Reach of MRD Detection in Lymphoma

September 5th 2024

Reid W. Merryman, MD, discusses notable advancements with minimal residual disease assays in lymphoma.

Elacestrant Improves PFS in ESR1-Mutant Metastatic Breast Cancer Subgroups

December 8th 2023

Treatment with elacestrant led to a clinically meaningful improvement in progression-free-survival compared with standard-of-care therapy among patients with estrogen receptor–positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Subgroup Analysis Shows Dostarlimab/Chemotherapy Elicits PFS Benefit in dMMR/MSI-H, TP53+, and NSMP Endometrial Cancer

October 23rd 2023

Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.

Frontline Itolizumab Elicits Durable Responses in aGVHD

February 17th 2023

First-line treatment with itolizumab produced rapid, durable responses and favorable safety in patients with acute graft-vs-host disease.

Pembrolizumab/Axitinib Combo Demonstrates Long-Term OS Benefit in Clear Cell RCC

September 16th 2021

Patients with clear cell renal cell carcinoma who received the combination of pembrolizumab and axitinib over sunitinib showed a benefit in adjusted overall survival and type and timing of subsequent therapy in a second interim analysis of the phase 3 KEYNOTE-426 study.

Frontline Pemigatinib Under Investigation in Advanced FGFR2+ Cholangiocarcinoma

July 2nd 2021

Single-agent pemigatinib is being compared with gemcitabine plus cisplatin in patients with unresectable and/or metastatic cholangiocarcinoma whose tumor harbor FGFR2 fusions or rearrangements in the ongoing, phase 3 FIGHT-302 trial.

Talquetamab at RP2D Elicits High Clinical Response Rate in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Talquetamab, when delivered at the recommended phase 2 dose of 405 µg/kg weekly, induced a high clinical response rate with favorable tolerabilty in patients with relapsed/refractory multiple myeloma.

Postoperative Radiotherapy Can Be Omitted Without Impacting Metastatic Risk in Low-Grade Breast Cancer

December 10th 2020

December 9, 2020 - Whole breast irradiation, following breast-conserving surgery and adjuvant endocrine therapy, can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years.

Neoadjuvant Apalutamide May Shrink Prostate Tumors

July 8th 2020

Interim data from a phase 2 study indicate that neoadjuvant hormone therapy may reduce tumor volume in men with high-risk prostate cancer planning to undergo radical prostatectomy.

Expert Calls for More Research in Checkpoint Blockade for Upper Tract Urothelial Cancers

December 21st 2015

Compelling evidence has been presented about the various checkpoint inhibitors in bladder cancer, but, additionally there have been some provocative papers looking at genomic sequencing of upper tract compared with bladder that shows certain differences